These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28073896)

  • 1. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
    Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
    Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
    Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
    Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
    ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
    Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
    Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
    Chen JH; Addanki S; Roy D; Bassett R; Kalashnikova E; Spickard E; Kuerer HM; Meas S; Sarli VN; Korkut A; White JB; Rauch GM; Tripathy D; Arun BK; Barcenas CH; Yam C; Sethi H; Rodriguez AA; Liu MC; Moulder SL; Lucci A
    BMC Cancer; 2024 Aug; 24(1):1016. PubMed ID: 39148033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
    Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
    Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
    Turner NC; Swift C; Jenkins B; Kilburn L; Coakley M; Beaney M; Fox L; Goddard K; Garcia-Murillas I; Proszek P; Hall P; Harper-Wynne C; Hickish T; Kernaghan S; Macpherson IR; Okines AFC; Palmieri C; Perry S; Randle K; Snowdon C; Stobart H; Wardley AM; Wheatley D; Waters S; Winter MC; Hubank M; Allen SD; Bliss JM;
    Ann Oncol; 2023 Feb; 34(2):200-211. PubMed ID: 36423745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
    Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
    Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
    PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
    Cailleux F; Agostinetto E; Lambertini M; Rothé F; Wu HT; Balcioglu M; Kalashnikova E; Vincent D; Viglietti G; Gombos A; Papagiannis A; Veys I; Awada A; Sethi H; Aleshin A; Larsimont D; Sotiriou C; Venet D; Ignatiadis M
    JCO Precis Oncol; 2022 Sep; 6():e2200148. PubMed ID: 36170624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
    Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
    Front Oncol; 2021; 11():736769. PubMed ID: 34868925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
    Nel I; Herzog H; Aktas B
    Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.